Aadi Bioscience, Inc. a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it presented data from its PRECISION 1 and AMPECT trials in two posters at the Society of Gynecological Oncology (SGO) Annual Meeting 2023, taking place March 25-28, 2023, in Tampa, FL.

"We are pleased to present additional data with nab-sirolimus from our AMPECT trial and highlight our PRECISION 1 trial at SGO 2023, which is the premier medical meeting focused on advancing research for gynecologic cancer," said Loretta Itri, MD., Chief Medical Officer of Aadi Bioscience.

The details of the poster presentations are below:

Title: "Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)"
Date and Time: Sunday, 3/26/2023, 2:00-3:00 PM
Session: Poster Session 1
Poster Number: 401

Title: "Response to treatment with nab-sirolimus among patients with primary uterine PEComa: A sub analysis from AMPECT"
Date and Time: Sunday, 3/26/2023, 2:00-3:00 PM
Session: Poster Session 1
Poster Number: 327

The Society of Gynecological Oncology Annual Meeting on Women's Cancer is the premier educational and scientific event for those who treat and care for women with gynecologic cancer.  Abstracts and full session details are available through the SGO Annual Meeting planner: Annual Meeting on Women's Cancer | SGO.  

The SGO posters are available on the investor relations page of the Aadi website at www.aadibio.com

 

Source:prnewswire.com

Report Abuse